Generic Name and Formulations:
Lipid content 0.2g/mL (refined soybean oil); emulsion for IV infusion; contains aluminum.
Indications for INTRALIPID:
To provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (≥5 days). To provide a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
Administer by IV infusion via a peripheral or central vein. Initiate rate at 0.5mL/min for the first 15–30mins; if tolerated, may increase to 1mL/min. Do not infuse >500mL on first day; if tolerated, may increase dose the next day; max: 2.5g/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 20%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Administer by IV infusion via a peripheral or central vein. Premature infants: initially 0.5g/kg/day; may increase based on ability to eliminate fat; max: 3g/kg/day. Older children: initiate rate at max 0.05mL/min for the first 10–15mins; if tolerated, may increase to 0.5mL/kg/hr. Max dose: 3g/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 20%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Disturbances of normal fat metabolism (eg, pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis if accompanied by hyperlipidemia).
Risk of deaths in preterm and low birth weight infants: see full labeling. Severe liver damage, pulmonary disease, anemia, blood coagulation disorders, or when there is danger of fat embolism. Monitor serum triglycerides, liver function in long-term use (discontinue if impaired), platelet counts in neonates. Pregnancy (Cat.C). Nursing mothers.
Sepsis, vein irritation, dyspnea, cyanosis, allergic reactions, hyperlipemia, hypercoagulability, nausea, vomiting, headache, flushing, increase in temperature, sweating, sleepiness, chest and back pain, dizziness, liver dysfunction, blood dyscrasias; aluminum toxicity (esp. preterm infants, renal impairment).
Emulsion (100mL, 250mL, 500mL)—1
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder